CN106539089A - A kind of complex prebiotics and its application - Google Patents
A kind of complex prebiotics and its application Download PDFInfo
- Publication number
- CN106539089A CN106539089A CN201610982930.0A CN201610982930A CN106539089A CN 106539089 A CN106539089 A CN 106539089A CN 201610982930 A CN201610982930 A CN 201610982930A CN 106539089 A CN106539089 A CN 106539089A
- Authority
- CN
- China
- Prior art keywords
- product
- inulin
- stachyose
- prebioticses
- complex prebiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 46
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 31
- 229920001202 Inulin Polymers 0.000 claims abstract description 28
- 229940029339 inulin Drugs 0.000 claims abstract description 28
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 25
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 23
- 239000008280 blood Substances 0.000 claims abstract description 19
- 210000004369 blood Anatomy 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 abstract description 15
- 235000018291 probiotics Nutrition 0.000 abstract description 12
- 239000006041 probiotic Substances 0.000 abstract description 11
- 230000000529 probiotic effect Effects 0.000 abstract description 11
- 238000000855 fermentation Methods 0.000 abstract description 8
- 230000004151 fermentation Effects 0.000 abstract description 8
- 230000036772 blood pressure Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 210000002429 large intestine Anatomy 0.000 abstract description 5
- 230000035790 physiological processes and functions Effects 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000000118 anti-neoplastic effect Effects 0.000 abstract description 3
- 210000001815 ascending colon Anatomy 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 235000008098 Oxalis acetosella Nutrition 0.000 abstract description 2
- 241001119522 Paullinia pinnata Species 0.000 abstract description 2
- 235000010240 Paullinia pinnata Nutrition 0.000 abstract description 2
- 230000037358 bacterial metabolism Effects 0.000 abstract description 2
- 235000013361 beverage Nutrition 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 28
- 230000000968 intestinal effect Effects 0.000 description 7
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 235000020880 diabetic diet Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A kind of complex prebiotics, the complex prebiotics are made up of 1 100 parts of 10 parts of stachyose and inulin by weight.This product take stachyose as leading, compatibility inulin, with the obvious advantage, makes the fermentation position of compositionss extend to whole large intestine, solves other prebioticses only the drawbacks of ascending colon ferments, can the big enteral of comprehensive propagation probiotic bacteria；Product function is very comprehensive, and existing flora optimizes function, can promote bacterial metabolism again, solves the deficiency that current prebioticses product is present on market；Also, after stachyose compatibility inulin, the physiological function of compositionss adjusts blood fat as reduced blood glucose and blood pressure, improves immunity of organisms, adjunct antineoplastic etc. and generates great synergistic function.This product can be used as the raw material or dispensing of beverage, bread and cheese, health food, special medicine purposes formula food and medicine.
Description
Technical field
The present invention relates to prebioticses, and in particular to a kind of complex prebiotics by stachyose compatibility inulin, while also
It is related to effect of the complex prebiotics in terms of blood sugar lowering and blood pressure, regulation blood fat, enhance immunity.
Background technology
Prebioticses be lost in a kind of modern diet, the dietary fiber beneficial to health, be that one kind can be selected
Selecting property is fermented and changes constituting and active composition of food to host health profitable strain in gastrointestinal tract.Prebioticses must are fulfilled for
Three conditions：1st, acidproof and hydrolytic enzyme, is not digested and assimilated with small intestinal by stomach；2nd, can be fermented by intestinal microbial population；3rd, can be optionally
The growth of the intestinal beneficial bacterium such as stimulation of bifidobacteria and lactobacilluss.
It is mainly oligosaccharide substance using more prebioticses at present, such as oligomeric galactose, inulin, oligofructose, low
Xylan, oligomeric isomaltose, soybean oligo saccharide, shitosan etc..The prebioticses product of those prebioticses compositions is mainly with following
Three kinds of modes are present：1st, make an addition in baby milk powder as additive；2nd, with little or minimum dosage and probiotic bacteria compatibility into conjunction
Raw unit's product；3rd, the prebioticses product of folk prescription abundance consumption.There is following defect in those prebioticses products：
1st, in symphysis unit product, prebioticses addition is too small, it is difficult to reach its minimum action consumption, it is more difficult to which playing prebioticses should
The physiological function of the performance.
2nd, the product such as symphysis unit and probiotic bacteria is not suitable for life-time service.Medical research proves, human body life-time service probiotic bacteria,
The ability that function of intestinal canal can be promoted progressively to lose self-reproduction probioticss, long human body intestinal canal will produce dependency, medically
Referred to as " probiotic bacteria dependence syndrome ".And human body once suffers from " probiotic bacteria dependence syndrome ", throughout one's life all will be by probiotic oral product
Come the health status for sustaining life.In addition, excessive use of probiotic bacteria is likely to become the new hotbed for breeding " superbug ".Due to
Many lactic acid bacterias have a multiple drug resistance to antibiotic, through with the community life of pathogen, contact, it is likely that will be self-contained
Drug resistance gene pass to pathogen, be allowed to obtain Drug resistance and become " superbug ", may can without medicine when causing infection
Doctor.
3rd, folk prescription prebioticses product limitation is big.In due to various oligosaccharides prebioticses, various oligosaccharide have each
Unique individual character, such as to the facilitation of various probiotic bacterias whether and strong and weak difference；To the rejection ability of various pernicious bacterias not
Together；In identical colon ecological environment, the time length of fermentation is different；In fermentation, produced gas flow is different；Fermentation
The species of the short-chain fatty acid produced during decomposition is different with amount；It is different in the Adhering capacity of big intestinal wall；In each region of big enteral
Fermentation activity is not equal so that folk prescription prebioticses product limitation is big.And design and adopt the compound recipe prebioticses product can be preferably
Solve the limitation of folk prescription prebioticses.
The content of the invention
The technical problem to be solved is：For above-mentioned the deficiencies in the prior art, there is provided a kind of formula is simplified, work(
Energy is complete, safety is natural and has the complex prebiotics by stachyose compatibility inulin of Synergistic, while also providing the compound benefit
Effect of the raw unit in terms of blood sugar lowering and blood pressure, regulation blood fat, enhance immunity.
In order to solve above-mentioned technical problem, the technical solution adopted in the present invention is：A kind of complex prebiotics, the compound benefit
Raw unit is made up of 10 parts of stachyose and inulin 1-100 parts by weight.
Preferably, the complex prebiotics are made up of 10 parts of stachyose and inulin 1-50 parts by weight.
Preferably, the complex prebiotics are made up of 10 parts of stachyose and inulin 50-100 parts by weight.
The complex prebiotics of the present invention are water intaking threose and inulin, and mixing stirs, prepared.
This complex prebiotics product introduces natural oligosaccharide --- stachyose.Stachyose is naturally occurring a kind of four
Sugar, belongs to oligomeric galactose, is not hydrolyzed by human digestive enzymes, can intactly enter colon, and by the zymolysis of intestinal bacteria institute, energy
Bacillus bifiduss propagation is remarkably promoted, is the excellent bacillus bifiduss proliferation activity factor.Stachyose is oligomeric as rare pure natural
Sugar substance. it is special with unique improvement the intestines and stomach, the liver protecting, reduction blood glucose blood pressure, regulation blood fat, auxiliary treatment chronic disease etc.
Function.It is leading with stachyose in this composition product, to promoting China's oligosaccharide and prebioticses industry development or weight will be produced
The strategic importance wanted.Also, another composition in compatibility is inulin, in inulin, it is more than 10 containing oligofructose and the degree of polymerization
Long-chain inulin, its fermenting speed fall between, and fermentation site distribution, can comprehensive propagation large intestine in the regional of large intestine
Interior probiotic bacteria.
The complex prebiotics product stachyose of the present invention is with the obvious advantage with inulin compatibility, expands the fermentation position of compositionss
To whole large intestine, solve other prebioticses only the drawbacks of ascending colon ferments, can the big enteral of comprehensive propagation probiotic bacteria.Plus
Stachyose there is unique improvement the intestines and stomach, the liver protecting, reduce blood glucose blood pressure, adjust the spies such as blood fat, auxiliary treatment chronic disease
The good physiological function of distinguished service energy, makes product function very comprehensive, can ferment in regions such as ascending colon, descending colon；Existing bacterium
Group's optimization function, can promote bacterial metabolism again, solve the deficiency that current prebioticses product is present on market.Also, stachyose
After compatibility inulin, the physiological function of compositionss adjusts blood fat as reduced diabeticss fasting glucose, blood pressure, improves body and exempts from
Epidemic disease power, adjunct antineoplastic etc. generate great synergistic function, make a concrete analysis of as follows：
1. the effect in terms of blood sugar lowering：
40 type 2 diabetes mellitus patients are recruited, after completing informed consent, is divided into matched group（10）, inulin group（10）, stachyose
Group（10）, stachyose+inulin group（10）Totally four groups, collective carries out a Knowledge About Diabetes Mellitus Among propaganda and education and diabetic diet
Education, and measure patient's fasting glucose（FGB）Index, averages as A.Matched group only takes Frank diabetes mellitus diet, inulin
Group takes Frank diabetes mellitus diet+12g inulin/day, stachyose group to take Frank diabetes mellitus diet+5g stachyose/day, this product
Group takes Frank diabetes mellitus diet+10g this products（Stachyose+inulin）The intervention stratege in/day, measures patient on an empty stomach again when 8 weeks
Blood glucose（FGB）Etc. index, average as B.Fasting glucose before and after calculating（FGB）Difference C, i.e. C=B-A, that is, each group is to sky
The impact of abdomen blood glucose（Reduce）Ability, is shown in Fig. 1.As a result show, the patient of stachyose group, inulin group and product group of the present invention is on an empty stomach
Blood glucose value decreases relative to matched group, and patient's fasting blood sugar of product group of the present invention significantly lower than stachyose group and
Inulin group, shows, product of the present invention has synergistic function well to reducing patient's fasting glucose.
From the foregoing, it will be observed that product of the present invention makes product fermentation position expansion using with the obvious advantage after stachyose and inulin compatibility
To whole large intestine；Simultaneously there is good coordination potentiation, powerful physiological function is brought, can reduce blood glucose and blood pressure,
Adjust blood fat, enhance immunity, adjunct antineoplastic.This product can be used as beverage, bread and cheese, health food, special medicine
The raw material or dispensing of way formula food and medicine is used.
Description of the drawings
Fig. 1 is product of the present invention to diabeticss fasting glucose index（FBG）Affect figure.
Specific embodiment
Embodiment 1
1 part of water intaking threose 10 and inulin, mixing, stir by weight, obtain final product the complex prebiotics product of the present invention.
Embodiment 2
30 parts of water intaking threose 10 and inulin, mixing, stir by weight, obtain final product the complex prebiotics product of the present invention.
Embodiment 3
50 parts of water intaking threose 10 and inulin, mixing, stir by weight, obtain final product the complex prebiotics product of the present invention.
Embodiment 4
70 parts of water intaking threose 10 and inulin, mixing, stir by weight, obtain final product the complex prebiotics product of the present invention.
Embodiment 5
100 parts of water intaking threose 10 and inulin, mixing, stir by weight, obtain final product the complex prebiotics product of the present invention.
Claims (5)
1. a kind of complex prebiotics, it is characterised in that the complex prebiotics are by weight by 10 parts of stachyose and inulin 1-100 parts
Composition.
2. complex prebiotics as claimed in claim 1, it is characterised in that the complex prebiotics are by weight by stachyose 10
Part and inulin 1-50 parts composition.
3. complex prebiotics as claimed in claim 1, it is characterised in that the complex prebiotics are by weight by stachyose 10
Part and inulin 50-100 parts composition.
4. application of the complex prebiotics described in claim 1 or 2 or 3 in diabeticss fasting glucose is reduced.
5. application of the complex prebiotics described in claim 1 or 2 or 3 in blood fat is adjusted.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610982930.0A CN106539089A (en) | 2016-11-09 | 2016-11-09 | A kind of complex prebiotics and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610982930.0A CN106539089A (en) | 2016-11-09 | 2016-11-09 | A kind of complex prebiotics and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106539089A true CN106539089A (en) | 2017-03-29 |
Family
ID=58394948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610982930.0A Pending CN106539089A (en) | 2016-11-09 | 2016-11-09 | A kind of complex prebiotics and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106539089A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107495383A (en) * | 2017-08-14 | 2017-12-22 | 北京市营养源研究所 | One kind relaxes bowel complex prebiotics and preparation method and application |
| CN107927789A (en) * | 2017-12-01 | 2018-04-20 | 刘峰 | A kind of prebiotics food and preparation method thereof |
| CN108719752A (en) * | 2017-04-24 | 2018-11-02 | 鲁南制药集团股份有限公司 | A kind of functional flour rich in nutritional ingredient |
| CN109006931A (en) * | 2017-06-09 | 2018-12-18 | 鲁南制药集团股份有限公司 | A kind of health-care moon cake |
| CN109007586A (en) * | 2017-06-09 | 2018-12-18 | 鲁南制药集团股份有限公司 | A kind of health nutritious noodle |
| CN109380635A (en) * | 2017-08-10 | 2019-02-26 | 赵同利 | A kind of inulin stachyose solid beverage |
| CN110432500A (en) * | 2019-08-07 | 2019-11-12 | 武汉英纽林生物科技有限公司 | A kind of prebiotic compositions and preparation method and purposes containing inulin |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104351786A (en) * | 2014-11-18 | 2015-02-18 | 厦门百泉利康生物科技有限公司 | Slimming food for changing lipophilic physique and processing method thereof |
| CN104783168A (en) * | 2015-05-05 | 2015-07-22 | 南昌康泰利保健品有限公司 | Compound nutritious powder for treating diarrhea |
| CN104855983A (en) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | Non-whole nutrient formula food for coronary heart disease |
-
2016
- 2016-11-09 CN CN201610982930.0A patent/CN106539089A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104351786A (en) * | 2014-11-18 | 2015-02-18 | 厦门百泉利康生物科技有限公司 | Slimming food for changing lipophilic physique and processing method thereof |
| CN104855983A (en) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | Non-whole nutrient formula food for coronary heart disease |
| CN104783168A (en) * | 2015-05-05 | 2015-07-22 | 南昌康泰利保健品有限公司 | Compound nutritious powder for treating diarrhea |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108719752A (en) * | 2017-04-24 | 2018-11-02 | 鲁南制药集团股份有限公司 | A kind of functional flour rich in nutritional ingredient |
| CN109006931A (en) * | 2017-06-09 | 2018-12-18 | 鲁南制药集团股份有限公司 | A kind of health-care moon cake |
| CN109007586A (en) * | 2017-06-09 | 2018-12-18 | 鲁南制药集团股份有限公司 | A kind of health nutritious noodle |
| CN109380635A (en) * | 2017-08-10 | 2019-02-26 | 赵同利 | A kind of inulin stachyose solid beverage |
| CN107495383A (en) * | 2017-08-14 | 2017-12-22 | 北京市营养源研究所 | One kind relaxes bowel complex prebiotics and preparation method and application |
| CN107927789A (en) * | 2017-12-01 | 2018-04-20 | 刘峰 | A kind of prebiotics food and preparation method thereof |
| CN110432500A (en) * | 2019-08-07 | 2019-11-12 | 武汉英纽林生物科技有限公司 | A kind of prebiotic compositions and preparation method and purposes containing inulin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106539089A (en) | A kind of complex prebiotics and its application | |
| JP4455333B2 (en) | Probiotic bacteria: Lactobacillus fermentum | |
| EP2604689B1 (en) | Anti-obesity agent and anti-obesity food | |
| Rolim | Development of prebiotic food products and health benefits | |
| Kolida et al. | Prebiotic effects of inulin and oligofructose | |
| JP7273725B2 (en) | Novel bifidobacterium bacterium and composition containing the bacterium | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| CN1731938A (en) | Prebiotic compositions | |
| WO2007140621A1 (en) | Probiotic compositions and uses thereof | |
| WO2007140622A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
| EA006441B1 (en) | Process and composition for decreasing inflammatory process ad/or abnormal activation of non-specific immune reaction | |
| CN109481510A (en) | It is a kind of to help to improve diabetes B and its synbiotic compound preparation of complication and preparation method thereof | |
| CN106615095A (en) | Sucrose-free functional yoghurt and preparation method thereof | |
| CN104415060A (en) | Edible composition as well as preparation method and application thereof | |
| CN111227261A (en) | Prebiotic composition and application thereof | |
| CA2995347A1 (en) | Materials and methods for improving gastrointestinal health | |
| CN107889997A (en) | A kind of Freeze-dry Powder of Probioctics solid beverage | |
| CN101965874B (en) | Dairy product for preventing and treating hypercholesterolemia | |
| CN110075226A (en) | It is a kind of can be with the probiotic composition of reducing blood lipid | |
| EP3722413A1 (en) | Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
| TWI719549B (en) | Prebiotic composition for promoting growth of akkermansia muciniphila | |
| CN106509917A (en) | Composite prebiotics and application thereof | |
| CN108936609B (en) | Nutritional preparation for elderly patients with swallowing dysfunction | |
| CN107242579A (en) | A kind of complex prebiotics and its application | |
| CN108523136A (en) | A kind of composition containing lactase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170329 |